ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the combination VS-6063, carboplatin, and
paclitaxel. in the treatment of patients with ovarian cancer. The study will evaluate whether
this regimen is safe. The study will also evaluate whether the regimen can reduce the amount
of cancerous cells in your body. If you agree, you will be treated with VS-6063 by mouth, as
well as carboplatin and paclitaxel infusions. Carboplatin and paclitaxel are approved by the
FDA for the treatment of ovarian cancer. VS-6063 is considered experimental because it is not
approved by the FDA for the treatment of cancer.